potential COVID-19 treatments - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.89 [0.77, 1.04]< 11%26 studies (26/-)93.4 %some concerncritical moderatecrucial-
death or transfer to ICU 0.65 [0.35, 1.22]< 10%1 study (1/-)90.9 %NAnot evaluable crucial-
deaths 0.88 [0.80, 0.97]< 111%47 studies (47/-)99.6 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.87 [0.72, 1.06]< 133%12 studies (12/-)91.8 %some concernlow moderatecrucial-
clinical deterioration 0.69 [0.52, 0.91]< 10%6 studies (6/-)99.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.15 [0.99, 1.33]> 161%21 studies (21/-)96.8 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.12 [0.84, 1.48]> 165%9 studies (9/-)78.0 %some concernserious moderateimportant-
clinical improvement (28-day) 1.24 [0.98, 1.57]> 138%13 studies (13/-)96.4 %some concerncritical moderateimportant-
clinical improvement (7-day) 1.54 [0.73, 3.24]> 149%5 studies (5/-)87.2 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.14 [1.02, 1.27]> 122%13 studies (13/-)99.0 %some concerncritical moderateimportant-
death or ventilation 0.80 [0.56, 1.15]< 139%5 studies (5/-)88.7 %some concernnot evaluable moderateimportant-
hospital discharge 0.96 [0.79, 1.15]> 153%7 studies (7/-)32.1 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.87 [0.66, 1.14]< 10%15 studies (15/-)83.9 %some concernlow moderateimportant-
mechanical ventilation (time to event analysis only) 0.72 [0.35, 1.48]< 10%2 studies (2/-)81.2 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 3.53 [1.19, 10.46]> 10%2 studies (2/-)98.9 %some concernnot evaluable moderateimportant-
viral clearance 6.97 [0.23, 210.35]> 189%2 studies (2/-)86.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 7.68 [0.34, 173.70]> 190%2 studies (2/-)89.7 %some concernnot evaluable moderateimportant-
ICU admission 0.63 [0.45, 0.87]< 10%8 studies (8/-)99.7 %some concernnot evaluable moderatenon important-
Major thrombotic events or death 1.04 [0.80, 1.36]< 10%1 study (1/-)38.7 %NAnot evaluable non important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %NAnot evaluable non important-
recovery 1.30 [0.64, 2.66]> 19%2 studies (2/-)76.5 %lownot evaluable highnon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %NAnot evaluable important-
serious adverse events 1.03 [0.86, 1.23]< 132%18 studies (18/-)39.3 %some concernlow moderateimportant-
superinfection 0.56 [0.15, 2.02]< 143%2 studies (2/-)81.2 %lownot evaluable highimportant-
adverse events 1.12 [0.96, 1.31]< 10%11 studies (11/-)7.8 %some concernlow moderatenon important-
deep vein thrombosis 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
elevated liver enzymes 0.36 [0.13, 1.01]< 10%1 study (1/-)97.3 %NAnot evaluable non important-
hyperbilirubinemia 1.09 [0.42, 2.79]< 10%1 study (1/-)43.1 %NAnot evaluable non important-
long QT 0.90 [0.56, 1.43]< 10%1 study (1/-)67.1 %NAnot evaluable non important-
Major bleeding 1.56 [0.85, 2.87]< 10%2 studies (2/-)7.7 %some concernnot evaluable moderatenon important-
pulmonary embolism 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
renal impairment 1.44 [0.98, 2.10]< 10%2 studies (2/-)3.0 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

Thromboembolic events 1.07 [0.76, 1.49]< 10%1 study (1/-)35.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.